Aspen Aerogels (NYSE:ASPN) Price Target Raised to $28.00 at Canaccord Genuity Group

Aspen Aerogels (NYSE:ASPN) had its price objective raised by Canaccord Genuity Group from $18.00 to $28.00 in a report published on Friday, Benzinga reports. They currently have a buy rating on the construction company’s stock.

A number of other equities analysts have also commented on the company. HC Wainwright lifted their price objective on Aspen Aerogels from $20.00 to $25.00 and gave the stock a buy rating in a research note on Friday. B. Riley lifted their target price on Aspen Aerogels from $24.00 to $30.00 and gave the stock a buy rating in a research report on Friday. Roth Mkm reaffirmed a buy rating and issued a $22.00 price target on shares of Aspen Aerogels in a report on Tuesday. Piper Sandler lifted their price target on shares of Aspen Aerogels from $20.00 to $29.00 and gave the stock an overweight rating in a research note on Friday. Finally, TheStreet upgraded shares of Aspen Aerogels from a d+ rating to a c- rating in a research note on Wednesday, March 6th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $25.17.

Aspen Aerogels Stock Up 5.3 %

NYSE:ASPN traded up $1.26 during mid-day trading on Friday, reaching $25.11. The stock had a trading volume of 3,351,897 shares, compared to its average volume of 1,155,989. The company has a current ratio of 3.41, a quick ratio of 2.91 and a debt-to-equity ratio of 0.24. The business’s 50 day moving average is $16.72 and its 200 day moving average is $13.69. Aspen Aerogels has a fifty-two week low of $5.32 and a fifty-two week high of $25.65.

Aspen Aerogels (NYSE:ASPN) last released its quarterly earnings results on Tuesday, February 13th. The construction company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.11. Aspen Aerogels had a negative net margin of 10.73% and a negative return on equity of 6.54%. The business had revenue of $84.22 million for the quarter, compared to the consensus estimate of $83.82 million. During the same quarter last year, the firm earned ($0.20) EPS. As a group, equities research analysts anticipate that Aspen Aerogels will post 0.03 EPS for the current fiscal year.

Institutional Trading of Aspen Aerogels

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Banque Cantonale Vaudoise boosted its holdings in Aspen Aerogels by 37.5% during the first quarter. Banque Cantonale Vaudoise now owns 4,593 shares of the construction company’s stock worth $81,000 after buying an additional 1,252 shares during the last quarter. McAdam LLC bought a new stake in Aspen Aerogels in the fourth quarter valued at approximately $191,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Aspen Aerogels by 71.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 23,052 shares of the construction company’s stock valued at $198,000 after purchasing an additional 9,601 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Aspen Aerogels by 38.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,971 shares of the construction company’s stock worth $205,000 after purchasing an additional 3,607 shares during the period. Finally, Cornerstone Investment Partners LLC bought a new position in shares of Aspen Aerogels during the fourth quarter worth $230,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.